Flora Growth (NASDAQ: FLGC), an all-outdoor cultivator and manufacturer of cannabis-derived products and brands, as signed a Letter of Intent (“LOI”) with Evergreen Pharmacare Pty Ltd. Evergreen is a licensed importer and distributor of medical cannabis products based in Australia, and the LOI calls for Flora to provide raw and finished medical cannabis products for medical cannabis patients. Flora plans to ship the medical-grade cannabis products after the company obtains the correct export licenses and completes its first commercial harvest. The LOI is the second that Flora has signed since recent changes in Colombian law allow the company to sell and export raw cannabis materials, namely dried flower, in addition to derivatives. According to the company, the Australian medical cannabis market is forecast to surpass AU$200 million in 2021 and US$1.5 billion by 2025; some experts forecast that the pharmacist-only CBD market in Australia will reach AU$250 million with approximately 2 million consumers. A key factor in this growth is the decision by the Australian government to move cannabidiol (“CBD”) from Schedule 4 to Schedule 3, which makes it permissible to sell and buy CBD products over the counter. “The agreement with Evergreen will allow us to establish a local partner in Australia while generating incremental revenue from our Colombian cannabis facility and as legislation evolves within Australia,” said Flora Growth chief revenue officer Jason Warnock in the press release. “This agreement also provides significant potential upside by allowing us to work with Australian regulators directly and bring our premium brands and established product formulations to the over-the-counter CBD market. Down-scheduling CBD fits well with Flora’s long-term consumer product strategy of providing proven cannabinoid wellness and beauty products to consumers around the world and we are excited to work with our partners on this new opportunity.”
To view the full press releases, visit https://ibn.fm/hVMuW
About Flora Growth Corp.
Flora Growth is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. For more information about the company, please visit www.FloraGrowth.ca.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.